Abstracts tagged "patient outcomes"

Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
Jennifer Rammel¹, Kristen Staggers ², Satid Thammasitboon ², Jorge Coss Bu ², Amanda Brown ³ and Eyal Muscal ⁴, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Baylor College of Medicine, Houston, ⁴Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 416 • 2019 ACR/ARP Annual Meeting
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Josep Verges¹, Marianna Vitaloni ¹, Rosa Sciortino ², Maritza Quintero ², Marco Bibas ¹, Jordi Monfort ³, Francisco de Abajo ⁴, Marco Matucci-Cerinic ⁵, Patrick du Souich ⁶, Ingrid Möller ⁷, Guy Eakin ⁸ and Angie Botto-van Bemden ⁸, ¹Osteoarthritis International Foundation, Barcelona, Spain, ²De los Andes University, Merida, Venezuela, ³Hospital del Mar, Barcelona, Spain, ⁴Universidad de Alcalá, Madrid, Spain, ⁵University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta
Background/Purpose: Knee OA (KOA) associates with remarkable functional restrictions due to pain that seriously affect social and emotional well-being, reducing the quality of life (QoL).…
Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting
The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Irena Doubelt¹, David Cuthbertson ², Gunnar Tomasson ³, Simon Carette ¹, Nader A. Khalidi ⁴, Curry L. Koening ⁵, Carol Langford ⁶, Carol A. McAlear ⁷, Larry W. Moreland ⁸, Paul Monach ⁹, Philip Seo ¹⁰, Ulrich Specks ¹¹, Antoine Sreih ¹², Kalen Young ¹³, Steven Ytterberg ¹¹, Peter A. Merkel ¹⁴, Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹⁵, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah Hospital, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Johns Hopkins Medicine, Baltimore, MD, ¹¹Mayo Clinic College of Medicine, Rochester, MN, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Vasculitis Foundation, Kansas City, MO, ¹⁴Univeristy of Pennsylvania, Philadelphia, PA, ¹⁵University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Asmir Vodencarevic ¹, David Simon ², Fabian Hartmann ², Michaela Reiser ², Axel Hueber ², Koray Tascilar ³, Arnd Kleyer ⁴, Marcus Zimmermann-Rittereiser ¹ and Georg Schett⁵, ¹Siemens Healthcare GmbH, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable remission may be feasible in a subset of patients…
Abstract Number: 421 • 2019 ACR/ARP Annual Meeting
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Vibeke Strand¹, Philip Mease ², Ervant Maksabedian ³, Bradley Stolshek ³, Lyrica Liu ³, David Collier ³, Gregory Kricorian ³ and Joseph Merola ⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Health-related quality of life is impacted in patients (pts) with psoriatic arthritis (PsA). Patient-reported outcomes (PROs) are an important means of measuring treatment improvements…
Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Nathalie Carrier ¹, Sophie Roux ², Ariel Masetto ², Artur deBrum Fernandes ², Patrick Liang ², Meryem Maoui ³ and Gilles Boire², ¹CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
Abstract Number: 438 • 2019 ACR/ARP Annual Meeting
Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?
Marilyn Wan¹, Jessica Walsh ², M. Elaine Husni ³, Jose Scher ⁴, Soumya Reddy ⁵ and Alexis Ogdie ⁶, ¹University of Pennsylvania, Philadelphia, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁵Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: The multi-dimensional health assessment questionnaire (MDHAQ) is a patient-reported outcome that is commonly used in clinical practice in the US and comprises of 10…
Abstract Number: 439 • 2019 ACR/ARP Annual Meeting
Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection
Daniel Furst¹, George Wan ², Jingyu Liu ³, Julie Zhu ³, Laura Bartels-Peculis ³, Mary Panaccio ³ and Roy Fleischmann ⁴, ¹University of California, Los Angeles, CA, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive inflammation and irreversible joint damage. Treatment of active disease includes disease-modifying anti-rheumatic drugs (DMARDs)…
Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…

1
2
3
…
8
Next Page »